- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2019
- Public Summary Document (PSD) March 2019 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2019 PBAC Meeting - Word
Daratumumab – March 2019
Daratumumab: Solution concentrate for I.V infusion 100 mg in 5 mL, Solution concentrate for I.V infusion 400 mg in 20 mL; Darzalex®
Last updated
5 July 2019